D-0506-2023 Class II Terminated
FDA drug recall D-0506-2023 was initiated by Preferred Pharmaceuticals, Inc. on Mar 27, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination. The recall status is terminated (terminated Oct 24, 2023). Affected quantity: 33 x 30-count; 78 x 60-count bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Apr 12, 2023
- Initiation Date
- Mar 27, 2023
- Termination Date
- Oct 24, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 33 x 30-count; 78 x 60-count bottles
Product Description
Alprazolam Tab, USP 1mg, (CIV), packaged in: a) 30-count bottle (NDC 68788-7596-3), b) 60-count bottle (NDC68788-7596-6); Rx Only, Preferred Pharmaceuticals, Inc. Manufactured by: Breckenridge Pharmaceuticals, Inc., Boca Raton, FL.
Reason for Recall
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
Distribution Pattern
Nationwide in the USA
Code Information
Lot # a) H3122D, Exp. Date:8/31/2024; b) Lot #A1123R, L0522E, J2622H, I1622F, H2422E, Exp. Date:8/31/2024.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0506-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026